Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1681
    +0.0025 (+0.21%)
     

  • GBP/USD

    1.2497
    -0.0014 (-0.11%)
     

  • Bitcoin GBP

    51,260.92
    -486.86 (-0.94%)
     

  • CMC Crypto 200

    1,332.51
    -64.03 (-4.58%)
     

  • S&P 500

    5,109.38
    +60.96 (+1.21%)
     

  • DOW

    38,321.63
    +235.83 (+0.62%)
     

  • CRUDE OIL

    83.94
    +0.37 (+0.44%)
     

  • GOLD FUTURES

    2,350.00
    +7.50 (+0.32%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Merck KGaA, Pfizer's immunotherapy fails in lung cancer trial

Reuters

FRANKFURT (Reuters) - Merck KGaA and Pfizer's cancer drug Bavencio could not be shown to improve survival in lung cancer patients that had previously undergone unsuccessful chemotherapy, Merck said.

The results revealed on Thursday mark another setback for a drug that is a late starter in the rapidly evolving field of cancer immunotherapies.

Merck shares turned negative following the news, trading 1.1 percent lower.

(Reporting by Ludwig Burger; Editing by Edward Taylor)